RayKnowChina Research Map
Shortlist

Zhongshan

Zhongshan City People's Hospital

中山市人民医院

Listed for 6 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Zhongshan City People's Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌5 papers led5 open trials led
  2. Hepatocellular carcinoma肝细胞癌9 papers led1 open trial led
  3. Osteosarcoma骨肉瘤1 paper led
  4. Neuroblastoma神经母细胞瘤1 paper led
  5. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  6. IgA nephropathyIgA 肾病1 paper led

Not listed for: Oesophageal squamous cell carcinoma, Stomach cancer, Hepatoblastoma, Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 5 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
7
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
12
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 2220242025: 112025

3 hospitals in Zhongshan for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 17

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2023-02
    Registry
    NCT05884983

    Age 30 years to 69 years (registered criteria)

    Led by Zhongshan City People's HospitalZhongshan

  2. Recruiting
    Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma
    Phase
    N/A
    Started
    2023-08
    Registry
    NCT05994170

    Age 18 years to 70 years (registered criteria)

    Led by Zhongshan City People's HospitalZhongshan

  3. Recruiting
    Xerostomia-optimised IMRT Versus Standard IMRT in NPC
    Phase
    N/A
    Started
    2023-10
    Registry
    NCT06282497

    Age 18 years to 70 years (registered criteria)

    Led by Zhongshan City People's HospitalZhongshan

  4. Recruiting
    Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City
    Phase
    Not given
    Started
    2020-04
    Registry
    NCT04085900

    Age 30 years to 69 years (registered criteria)

    Led by Zhongshan City People's Hospital; 1 listed hospital as study siteWuzhou, Zhongshan

  5. Not yet recruiting
    Development and Validation of a Biopsy Decision Model for Nasopharyngeal Carcinoma Based on Serological Markers and Endoscopic Features
    Phase
    Not given
    Started
    2026-11
    Registry
    NCT07918755

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan City People's Hospital; 1 listed hospital as study siteNanning, Zhongshan

  6. Recruiting
    Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2026-07
    Registry
    NCT07661771

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 6 listed hospitals as study sitesChangsha, Dongguan, Foshan, Guangzhou, Shenzhen, Zhongshan

  7. Recruiting
    QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    Phase
    Phase 3
    Started
    2025-05
    Registry
    NCT06749899

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 17 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xiamen, Zhongshan

  8. Recruiting
    A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
    Phase
    Phase 2
    Started
    2025-04
    Registry
    NCT06839066

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Dongguan, Fuzhou, Ganzhou, Guangzhou, Hangzhou, Nanning, Shenzhen, Wuhan, Zhongshan

  9. Recruiting
    Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
    Phase
    Phase 2
    Started
    2025-06
    Registry
    NCT07070479

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesChangsha, Guangzhou, Zhongshan, Zhuhai

  10. Recruiting
    Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328841

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Wuhan, Wuzhou, Zhongshan, Zhuhai

  11. Recruiting
    40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328854

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shantou, Wuzhou, Zhongshan, Zhuhai

  12. Recruiting
    Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal Carcinoma
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06445088

    Age not stated (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 4 listed hospitals as study sitesFuzhou, Guangzhou, Nanning, Wuzhou, Zhongshan

  13. Recruiting
    Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2021-03
    Registry
    NCT04778956

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 6 listed hospitals as study sitesFoshan, Guangzhou, Zhongshan

  14. Recruiting
    Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-08
    Registry
    NCT04448522

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 3 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan

  15. Recruiting
    Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-07
    Registry
    NCT04453813

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan, Zhuhai

  16. Recruiting
    Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2020-09
    Registry
    NCT04453826

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesGuangzhou, Shaoguan, Wuzhou, Zhongshan, Zhuhai

  17. Recruiting
    Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma Patients
    Phase
    N/A
    Started
    2017-10
    Registry
    NCT03353467

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesFoshan, Guangzhou, Nanning, Zhongshan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrent / metastatic diseaseImaging & AISide effects & quality of life
Departments in papersRadiation oncologyENT / head & neck surgeryPathology / laboratory medicineNasopharyngeal carcinoma dept.
Papers it led5
  1. Specific Selective Neck Dissection for Isolated Regional Failure in Nasopharyngeal Carcinoma after Radiation.2025Ear, nose, & throat journal
  2. Optimal Size Threshold for MRI-Detected Retropharyngeal Lymph Nodes to Predict Outcomes in Nasopharyngeal Carcinoma: A Two-Center Study.2024AJR. American journal of roentgenology
  3. Radiation-induced nasopharyngeal necrosis combined with local recurrence in nasopharyngeal carcinoma: diagnosis and treatment strategies.2024Expert review of anticancer therapy
  4. A prediction model for xerostomia in locoregionally advanced nasopharyngeal carcinoma patients receiving radical radiotherapy.2022BMC oral healthRCTFree full text
  5. A positive feedback loop between LINC01605 and NF-κB pathway promotes tumor growth in nasopharyngeal carcinoma.2022RNA biologyFree full text
Chinese-language papers (not in the count)2
  1. [Villin-like protein VILL suppresses proliferation of nasopharyngeal carcinoma cells by interacting with LMO7 protein].2025Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
  2. [Net survival analysis of cancer in Zhongshan City of Guangdong Province in China, 1970 to 2014].2024Zhonghua zhong liu za zhi [Chinese journal of oncology]
All its trials on ClinicalTrials.gov, any status22
  1. Development and Validation of a Biopsy Decision Model for Nasopharyngeal Carcinoma Based on Serological Markers and Endoscopic FeaturesNot yet recruitingNCT07918755Lead sponsorStart 2026-11
  2. Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal CarcinomaRecruitingNCT05884983Lead sponsorStart 2023-02
  3. Xerostomia-optimised IMRT Versus Standard IMRT in NPCRecruitingNCT06282497Lead sponsorN/AStart 2023-10
  4. Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal CarcinomaRecruitingNCT05994170Lead sponsorN/AStart 2023-08
  5. Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan CityRecruitingNCT04085900Lead sponsorStart 2020-04
  6. Anrotinib and Tirelizumab in First-line Treatment of RM-NPCStatus unknownNCT05981157Lead sponsorPhase 2Start 2023-06
  7. Nasopharyngeal Carcinoma Screening in Zhongshan CityStatus unknownNCT02501993Lead sponsorStart 2012-03
  8. Individualized Primary Clinical Target Volume Based on Margin Expansion for Nasopharyngeal CarcinomaRecruitingNCT07661771Study sitePhase 3Start 2026-07
  9. Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and ImmunotherapyRecruitingNCT07328841Study sitePhase 3Start 2025-11
  10. Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II TrialRecruitingNCT07070479Study sitePhase 2Start 2025-06
  11. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.RecruitingNCT06749899Study sitePhase 3Start 2025-05
  12. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaRecruitingNCT07328854Study sitePhase 3Start 2025-11
  13. A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line TherapyRecruitingNCT06839066Study sitePhase 2Start 2025-04
  14. Diagnostic Accuracy of EBV C Promoter Methylation Kit in Nasopharyngeal CarcinomaRecruitingNCT06445088Study siteStart 2024-05
  15. Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal CarcinomaRecruitingNCT04778956Study sitePhase 3Start 2021-03
  16. Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal CarcinomaRecruitingNCT04453826Study sitePhase 3Start 2020-09
  17. Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal CarcinomaRecruitingNCT04453813Study sitePhase 3Start 2020-07
  18. Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal CarcinomaRecruitingNCT04448522Study sitePhase 3Start 2020-08
  19. Endoscopic Nasopharyngectomy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma PatientsRecruitingNCT03353467Study siteN/AStart 2017-10
  20. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05126719Study sitePhase 2Start 2023-04
  21. Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal CarcinomaActive, not recruitingNCT05979961Study sitePhase 3Start 2023-09
  22. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Study siteStart 2022-03
More papers found outside PubMed (not counted)17
  1. Abstract 4686: Efficacy and safety of efbemalenograstim alfa as primary prophylaxisfor concurrent chemo-radiotherapy induced neutropenia2025Cancer Researchconference-abstract
  2. Becotatug vedotin vs. chemotherapy in pre-heavily treated advanced nasopharyngeal carcinoma: A randomized, controlled, multicenter, open-label study.2025Journal of Clinical Oncologyarticle
  3. LBA35 Iza-Bren (BL-B01D1), an EGFR×HER3 bispecific antibody-drug conjugate, versus physician's choice of chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma: A randomized, open-label, multicenter, phase III, piv2025Annals of Oncologyconference-abstract
  4. Novel genetic algorithm‐based individual treatment effect scoring model for optimizing decision‐making: Induction chemotherapy in nasopharyngeal carcinoma2025Open Research (University of Surrey)article
  5. Tagitanlimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (R/M NPC): Results from a randomized, double-blind, phase 3 study.2025Journal of Clinical Oncologyconference-abstract
  6. Tertiary lymphoid structures: Defining immune subtypes and enabling precision immunotherapy in nasopharyngeal carcinoma2025Clinical and Translational Discoveryarticle
  7. A prospective multicenter trial of dose escalation for weekly gemcitabine concurrent with intensity-modulated radiotherapy following cisplatin and gemcitabine induction chemotherapy in patients with locally advanced nasopharyngeal carcinoma2024Journal of Clinical Oncologyconference-abstract
  8. Radiotherapy Target Volume Delineation Based on Post-Induction Chemotherapy Gross Tumor Volume vs. Pre-Induction Volume for Locoregionally Advanced Nasopharyngeal Carcinoma: An Open-label, Non-Inferiority, Multicenter, Randomized Phase III 2024International Journal of Radiation Oncology*Biology*Physicsarticle
  9. The efficacy and safety of ulinastatin in the prevention and treatment of radiotherapy-induced oral mucositis in locoregionally advanced nasopharyngeal carcinoma (LA-NPC): A multicenter, open-label, randomized controlled clinical trial.2024Journal of Clinical Oncologyconference-abstract
  10. 860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma2023Annals of Oncologyarticle
  11. Data from Epstein-Barr Virus Induces Lymphangiogenesis and Lympth Node Metastasis via Upregulation of VEGF-C in Nasopharyngeal Carcinoma2023Venue not listedother
  12. MRI Characteristics and Treatment Strategies of Radiation-Induced Nasopharyngeal Necrosis Combined with Local Recurrence in Nasopharyngeal Carcinoma: A Retrospective Study2023SSRN Electronic Journalpreprint
  13. Novel antibody biomarker P85-Ab improved the performance of nasopharyngeal carcinoma screening2023Chinese Science Bulletin (Chinese Version)article
  14. Study on the diagnostic value of BNLF2b in nasopharyngeal carcinoma2023Research Squarepreprint
  15. The dynamic Epstein-Barr virus-related serological monitor on a large-scale population-based screening cohort: a ten-year prospective follow-up study2023Research Squarepreprint
  16. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncologyarticle
  17. Epstein-Barr virus-based nasopharyngeal carcinoma population screening2021Annals of Nasopharynx Cancerarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 9 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.06%.

Papers led
9
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 2220232024: 4420242025: 112025

2 hospitals in Zhongshan for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan City
    Phase
    Not given
    Started
    2025-03
    Registry
    NCT07010198

    Age 35 years to Not stated (registered criteria)

    Led by Zhongshan City People's HospitalZhongshan

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRecurrence & prognosisSurgery & liver transplantLocal treatment (ablation, TACE, HAIC)
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatology
Papers it led9
  1. Efficacy evaluation of postoperative adjuvant transarterial chemoembolization in preventing hepatocellular carcinoma recurrence within the Milan criteria: A multicenter propensity score matching analysis based on pathologic indicators.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  2. Monitoring Hepatocellular Carcinoma Using Tumor Content in Circulating Cell-Free DNA.2024Clinical cancer research : an official journal of the American Association for Cancer Research
  3. Association Between Prediabetes and Risk, Mortality of Hepatocellular Carcinoma: A Meta-Analysis.2024Endocrine research
  4. Development and validation of nomograms to evaluate the survival outcome of HCC patients undergoing selective postoperative adjuvant TACE.2024La Radiologia medicaRCT
  5. Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma.2024World journal of gastroenterologyFree full text
  6. Preoperative transcatheter arterial chemoembolization and prognosis of patients with solitary large hepatocellular carcinomas (≥5 cm): Multicenter retrospective study.2023Cancer medicineFree full text
  7. Preoperative alkaline phosphatase-to-platelet count ratio as a prognostic factor for hepatocellular carcinoma with microvascular invasion.2023Cancer medicineFree full text
  8. Clinical efficacy of targeted therapy, immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX), and lipiodol embolization in the treatment of unresectable hepatocarcinoma.2022Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  9. Survival analysis between laparoscopic and open hepatectomy for hepatocellular carcinoma: a meta-analysis based on reconstructed time-to-event data.2021Hepatology international
All its trials on ClinicalTrials.gov, any status2
  1. Head-to-Head Comparison of Hepatocellular Cancer (HCC) Screening Strategies: A Prospective Population-Based Cohort Study in Zhongshan CityRecruitingNCT07010198Lead sponsorStart 2025-03
  2. Hepatocellular Cancer (HCC) Screening in Zhongshan CityStatus unknownNCT02501980Lead sponsorStart 2012-01

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 1 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Zhongshan for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 1 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.09%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

3 hospitals in Zhongshan for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Zhongshan for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 1 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Zhongshan for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics
Papers it led1
  1. Tph cells are expanded in IgA vasculitis nephritis.2025Molecular immunology

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

中山市人民医院

Zhongshan City People's Hospital

中山

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Zhongshan People's Hospital; Zhongshan People's Hospital Affiliated to Guangdong Medical University; Tumor Hospital of Zhongshan People's Hospital; Zhongshan City People's Hospital Affiliated to Sun Yat-sen University; Zhongshan City People' s Hospital

Suggest a correctionDownload the data